The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover
NCT04403698
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Erosive Osteoarthritis
Interventions
DRUG:
Alendronate Effervescent Oral Tablet
Sponsor
University Hospital, Ghent
Collaborators
[object Object]
[object Object]